(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 58.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Apellis Pharmaceuticals's revenue in 2024 is $396,591,000.On average, 8 Wall Street analysts forecast APLS's revenue for 2024 to be $94,735,654,011, with the lowest APLS revenue forecast at $85,969,963,767, and the highest APLS revenue forecast at $110,908,681,095. On average, 8 Wall Street analysts forecast APLS's revenue for 2025 to be $140,862,996,273, with the lowest APLS revenue forecast at $125,872,876,146, and the highest APLS revenue forecast at $151,624,314,463.
In 2026, APLS is forecast to generate $189,571,390,873 in revenue, with the lowest revenue forecast at $171,666,206,964 and the highest revenue forecast at $217,408,893,447.